GlassScriptPhysician profile
Arya Peter Salas
NPI 1124189030
$5,480.30
in general payments reported to CMS, 2019-2025
32 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what 75% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,094 · 2020: $160 · 2021: $63.46 · 2022: $286 · 2023: $1,389 · 2024: $1,249 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,583 · Travel and Lodging: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,582.95 |
| Travel and Lodging | $293.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $1,741.91 | 2021-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Kci USA, INC. | $779.18 | 2019-2023 | Prevena, V.A.C. Veraflo, Prevena Restor Bellaform |
| Kerecis Limited | $558.81 | 2022-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Surgiclose |
| Musculoskeletal Transplant Foundation INC. | $333.26 | 2019-2025 | |
| Organogenesis INC. | $258.34 | 2019-2025 | Puraply, Affinity, Apligraf |
| Abbvie INC. | $237.63 | 2023-2025 | Botox |
| Smith+Nephew, INC. | $226.71 | 2019-2025 | Grafix Pl, Oasis, Stravix Pl |
| Merz North America, INC. | $171.01 | 2019-2023 | Xeomin |
| Covidien LP | $125.00 | 2019 | |
| Csl Behring | $104.37 | 2024 | Kcentra |
| Acera Surgical, INC. | $103.37 | 2019-2025 | Restrata Wound Matrix |
| La Jolla Pharmaceutical Company | $97.05 | 2025 | Giapreza |
| Royal Biologics, INC. | $62.19 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $61.84 | 2024-2025 | |
| Biotissue Holdings INC. | $60.00 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $57.51 | 2024 | Daxxify |
| Allergan, INC. | $56.96 | 2019-2021 | |
| Solventum Corporation | $53.16 | 2024-2025 | Prevena, V.A.C.Instill, V.A.C.Ulta |
| Convatec INC. | $48.48 | 2019-2024 | |
| Mentor Worldwide LLC | $44.12 | 2022 | |
| Access Pro Medical, LLC | $36.27 | 2025 | Matriderm |
| Sientra, INC. | $34.75 | 2019 | |
| Polynovo North America LLC | $30.04 | 2023 | |
| Axogen | $29.78 | 2019 | |
| Lifenet Health | $28.16 | 2025 | Theragenesis Wound Matrix |
| Urgo Medical North America, LLC | $23.10 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Acell, INC. | $22.46 | 2020 | |
| Hydrofera LLC | $22.44 | 2024 | Hydrofera Blue |
| Next Science LLC | $20.55 | 2023 | Surgx, Blastx, Xperience |
| Heron Therapeutics, INC. | $20.05 | 2025 | Zynrelef |
| Baxter Healthcare | $17.20 | 2022 | |
| W. L. Gore & Associates, INC. | $14.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arya Salas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.